Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Poliomyelitis Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Poliomyelitis Overview | 10 | 1 |
| Pipeline Products for Poliomyelitis Comparative Analysis | 11 | 1 |
| Poliomyelitis Therapeutics under Development by Companies | 12 | 2 |
| Poliomyelitis Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Poliomyelitis Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Poliomyelitis Products under Development by Companies | 18 | 1 |
| Poliomyelitis Products under Investigation by Universities/Institutes | 19 | 1 |
| Poliomyelitis Companies Involved in Therapeutics Development | 20 | 17 |
| Beijing Minhai Biotechnology Co., Ltd | 20 | 1 |
| Beijing Tiantan Biological Products Co., Ltd. | 21 | 1 |
| Bharat Biotech International Limited | 22 | 1 |
| Bilthoven Biologicals B.V. | 23 | 1 |
| Biological E. Limited | 24 | 1 |
| Boryung Pharmaceutical Co., Ltd. | 25 | 1 |
| Codagenix, Inc. | 26 | 1 |
| Daiichi Sankyo Company, Limited | 27 | 1 |
| Grifols, S.A. | 28 | 1 |
| Johnson &Johnson | 29 | 1 |
| LG Life Science LTD. | 30 | 1 |
| Nanolek, LLC | 31 | 1 |
| Panacea Biotec Limited | 32 | 1 |
| Sanofi Pasteur SA | 33 | 1 |
| Sentinext Therapeutics Sdn Bhd | 34 | 1 |
| Sinovac Biotech Ltd. | 35 | 1 |
| Taiga Biotechnologies, Inc. | 36 | 1 |
| Poliomyelitis Therapeutics Assessment | 37 | 8 |
| Assessment by Monotherapy Products | 37 | 1 |
| Assessment by Combination Products | 38 | 1 |
| Assessment by Target | 39 | 2 |
| Assessment by Route of Administration | 41 | 2 |
| Assessment by Molecule Type | 43 | 2 |
| Drug Profiles | 45 | 28 |
| (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 1 |
| (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 1 |
| (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 1 |
| (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 3 |
| immune globulin (human) - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 2 |
| ImmunoRx - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| IPVGVI-3000 - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 1 |
| LBVC - Drug Profile | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 1 |
| LBVD - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| polio (monovalent) vaccine - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| polio (virus like particle, bivalent) vaccine - Drug Profile | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| polio [serotypes 1, 2, 3] (monovalent) vaccine - Drug Profile | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| polio [strain Sabin] vaccine - Drug Profile | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 1 |
| polio vaccine - Drug Profile | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 1 |
| polio vaccine - Drug Profile | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 1 |
| polio vaccine - Drug Profile | 67 | 1 |
| Product Description | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| R&D Progress | 67 | 1 |
| polio vaccine - Drug Profile | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| R&D Progress | 68 | 1 |
| polio vaccine - Drug Profile | 69 | 1 |
| Product Description | 69 | 1 |
| Mechanism of Action | 69 | 1 |
| R&D Progress | 69 | 1 |
| polio vaccine 2 - Drug Profile | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| poliomyelitis vaccine - Drug Profile | 71 | 1 |
| Product Description | 71 | 1 |
| Mechanism of Action | 71 | 1 |
| R&D Progress | 71 | 1 |
| VN-0105 - Drug Profile | 72 | 1 |
| Product Description | 72 | 1 |
| Mechanism of Action | 72 | 1 |
| R&D Progress | 72 | 1 |
| Poliomyelitis Recent Pipeline Updates | 73 | 1 |
| Poliomyelitis - Dormant Projects | 74 | 1 |
| Poliomyelitis Discontinued Products | 75 | 1 |
| Poliomyelitis Product Development Milestones | 76 | 4 |
| Featured News &Press Releases | 76 | 1 |
| Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur s Investigational Pediatric Hexavalent Vaccine | 76 | 1 |
| Mar 03, 2014: Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication | 77 | 1 |
| Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima | 77 | 1 |
| Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine | 78 | 1 |
| Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets | 78 | 2 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |